[PDF] Top 20 La artesanía chilena en los albores del siglo XXI.
Has 10000 "La artesanía chilena en los albores del siglo XXI." found on our website. Below are the top 20 most common "La artesanía chilena en los albores del siglo XXI.".
Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial
... with long- term treatment seems ...of donepezil in the 52-week study in AD patients were diarrhea ...increase from 5 to 10 mg suggests the need to pay attention to the oc- currence of ... See full document
46
Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial
... The results of our present study support our interpretation and the necessity of disease-specific brief psychosocial therapy in the lead-in period in future ... See full document
44
Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis : results from a phase IIa open‐label trial and subsequent phase III open‐label extension
... their long-term application is limited by adherence and risk of ...for use in adolescents with AD (ex- cept for systemic corticosteroids and ciclosporin in patients aged ≥ 16 years in certain ... See full document
111
Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
... randomized Phase III trial (ALEX study, NCT02075840), comparing alectinib and crizotinib in treatment-naive ALK-positive advanced NSCLC, may ... See full document
9
Behavior management approach for agitated behavior in Japanese patients with dementia: a pilot study
... with dementia are summarized in Table ...with dementia with Lewy bodies, n = 8) who participated in the intervention study, four patients suffering from dementia with Lewy ... See full document
8
Systemic Therapy of Advanced Renal Cell Carcinoma—Summary of Main Presentations at the ASCO, ASCO GU and ESMO 2012 Annual Meetings
... final results from the phase III TIVO-1 trial, in which tivozanib (AV-951), a highly po- tent new vascular endothelial growth factor receptor (VEGFR) targeting TKI, was prospectively ... See full document
158
Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
... Phase II, double blind, multinational trial which is planned to enroll 160 patients. The study design (Figure 3) involves randomization 1:1 to receive either tivozanib (1.5 mg daily 3 weeks on, 1 week off) ... See full document
9
Lasofoxifene: Evidence of its therapeutic value in osteoporosis
... Introduction: Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. It is a common disorder in elderly subjects and represents a major public health problem, ... See full document
6
Long term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open label study
... off-label use of the medication, we believe our study supports a clinically nuanced approach with dose escalation for most refractory patients, always with caution and close follow-up to monitor side ... See full document
19
A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer’s disease
... DLB, dementia with Lewy bodies; LBP, Lewy body pathology; LBV, Lewy body variant; n/a, not available; SDLT, senile dementia of Lewy body type; VaD, vascular ... See full document
102
Neuroimaging characteristics of dementia with Lewy bodies
... Recent advances in image processing allow automatic ex- traction of whole brain cortical thickness information from structural MRI. Cortical thickness has been shown to demonstrate high precision and sensitivity ... See full document
28
An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
... a Phase 1a study, 32 healthy volunteers received a single dose of lanadelumab (dose range ...a Phase 1b study, patients with HAE received two doses of lanadelumab (30, 100, 300 or 400 mg) or placebo, ... See full document
18
Plitidepsin: design, development, and potential place in therapy
... found from all Phase I studies of ...multicenter, open-label, Phase I–II study to determine the maximum tolerated dose and recom- mended dose of plitidepsin as a single agent in 38 ... See full document
8
Safety and effectiveness of nimotuzumab in high grade glioma patients. phase iv study results
... Nimotuzumab was used in all patients. In most of them (54.3%) the MoAb was given concurrently with RT. In 15.7% following the criteria of the treating physician, the MoAb treatment was given sequentially after completion ... See full document
8
Profile of perampanel and its potential in the treatment of partial onset seizures
... in Phase III studies and their open-label extension phase, only a minority of them achieved seizure freedom, a result similar to those previously reported over the last 20 years ... See full document
11
Comprehensive treatment of dementia with Lewy bodies
... disease [46]. There may also be qualitative differences. In Alzheimer’s disease, hallucinations generally have a threatening or fearful quality [47]. They are often ac- companied by delusions of suspicion [47]. In ... See full document
16
Tivozanib in the treatment of renal cell carcinoma
... make long-term treatment difficult or necessitate dose reductions and ...kinases. Phase II and III studies have demonstrated significant activity and favorable safety profile as initial ... See full document
9
<p>Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date</p>
... evaluations from investigators involved in RCTs have made it possible to emphasize the several obstacles to effective drug development in ...positive results in Phase II trials have recently failed ... See full document
49
Safety and efficacy of duloxetine in Japanese patients with chronic knee pain due to osteoarthritis: an open-label, long-term, Phase III extension study
... year, assuming an estimated maximum withdrawal rate of 30%. The safety analysis population included all enrolled patients who received at least one dose of study treatment. The efficacy analysis population included all ... See full document
7
Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies
... The COMPOSE-6 and COMPOSE-7 studies were single- arm, open-label, Phase III clinical studies. COMPOSE-6 was conducted across 21 sites, and COMPOSE-7 was conducted across nine sites, all in ... See full document
6
Related subjects